FI109659B - Levosimendaanin farmaseuttisia liuoksia - Google Patents
Levosimendaanin farmaseuttisia liuoksia Download PDFInfo
- Publication number
- FI109659B FI109659B FI991925A FI19991925A FI109659B FI 109659 B FI109659 B FI 109659B FI 991925 A FI991925 A FI 991925A FI 19991925 A FI19991925 A FI 19991925A FI 109659 B FI109659 B FI 109659B
- Authority
- FI
- Finland
- Prior art keywords
- levosimendan
- solution
- pharmaceutically acceptable
- solution according
- acid
- Prior art date
Links
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title claims description 63
- 229960000692 levosimendan Drugs 0.000 title claims description 63
- 239000003186 pharmaceutical solution Substances 0.000 title claims description 5
- 239000000243 solution Substances 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- 238000001990 intravenous administration Methods 0.000 claims description 33
- 239000012141 concentrate Substances 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003978 infusion fluid Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 18
- 239000008137 solubility enhancer Substances 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 239000008365 aqueous carrier Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 6
- -1 (-) - [[4- (1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl] hydrazono] Chemical class 0.000 description 5
- 101150044039 PF12 gene Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000008364 bulk solution Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 125000005638 hydrazono group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940114897 levosimendan 2.5 mg/ml Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940105067 sodium chloride 9 mg/ml Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (41)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI991925A FI109659B (fi) | 1999-09-10 | 1999-09-10 | Levosimendaanin farmaseuttisia liuoksia |
| UA2002042873A UA73954C2 (uk) | 1999-09-10 | 2000-08-09 | Водний розчин для внутрішньовенного введення та фармацевтичний розчин, що містять левосимендан |
| MYPI20003682A MY125984A (en) | 1999-09-10 | 2000-08-11 | Pharmaceutical solutions of levosimendan. |
| ARP000104525A AR025449A1 (es) | 1999-09-10 | 2000-08-30 | Soluciones farmaceuticas de levosimendan |
| TW089117581A TWI242434B (en) | 1999-09-10 | 2000-08-30 | Pharmaceutical solutions of levosimendan |
| CO00067212A CO5180582A1 (es) | 1999-09-10 | 2000-09-06 | Soluciones farmaceuticas de levosimendan |
| US10/070,689 US6730673B1 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| NZ517605A NZ517605A (en) | 1999-09-10 | 2000-09-08 | Levosimendan solutions at a pH less than 5 particularly for intravenous administration |
| MEP-2008-866A ME00523B (me) | 1999-09-10 | 2000-09-08 | Farmaceutski rastvori levosimendana |
| DE60025627T DE60025627T2 (de) | 1999-09-10 | 2000-09-08 | Pharmazeutische lösung von levosimendan |
| HU0202749A HU228340B1 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| SK327-2002A SK287154B6 (sk) | 1999-09-10 | 2000-09-08 | Vodný intravenózny infúzny roztok alebo farmaceutický roztok obsahujúci levosimendan |
| ES00958562T ES2256034T3 (es) | 1999-09-10 | 2000-09-08 | Soluciones farmaceuticas de levosimendano. |
| HK03101189.6A HK1049282B (zh) | 1999-09-10 | 2000-09-08 | 左西孟旦的藥物溶液 |
| TR2002/00620T TR200200620T2 (tr) | 1999-09-10 | 2000-09-08 | Levosimendan farmasötik solüsyonları |
| EP00958562A EP1210085B1 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| EA200200348A EA005067B1 (ru) | 1999-09-10 | 2000-09-08 | Фармацевтические растворы левосимендана |
| KR20027002923A KR100869752B1 (ko) | 1999-09-10 | 2000-09-08 | 레보시멘단의 약학적 액제 |
| IL14837900A IL148379A0 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| PL354028A PL202356B1 (pl) | 1999-09-10 | 2000-09-08 | Wodny roztwór do infuzji dożylnej i kompozycja farmaceutyczna w postaci roztworu |
| EEP200200129A EE05375B1 (et) | 1999-09-10 | 2000-09-08 | LevosimendaniÁfarmatseutilineÁlahus |
| CA002382013A CA2382013C (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| YUP-169/02A RS50445B (sr) | 1999-09-10 | 2000-09-08 | Farmaceutski rastvori levosimendana |
| BRPI0013924A BRPI0013924B8 (pt) | 1999-09-10 | 2000-09-08 | soluções farmacêuticas de levosimendano |
| CNB008126453A CN1203855C (zh) | 1999-09-10 | 2000-09-08 | 左西孟旦的药物溶液 |
| HR20020298A HRP20020298B1 (hr) | 1999-09-10 | 2000-09-08 | Farmaceutske otopine levosimendana |
| CZ20020788A CZ303095B6 (cs) | 1999-09-10 | 2000-09-08 | Vodný intravenosní infusní roztok nebo farmaceutický roztok obsahující levosimendan |
| DK00958562T DK1210085T3 (da) | 1999-09-10 | 2000-09-08 | Farmaceutiske oplösninger af levosimendan |
| JP2001522969A JP4708648B2 (ja) | 1999-09-10 | 2000-09-08 | レボシメンダンの医薬溶液 |
| SI200030801T SI1210085T1 (sl) | 1999-09-10 | 2000-09-08 | Farmacevtske raztopine levosimendana |
| AU70044/00A AU771027B2 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| MXPA02002423A MXPA02002423A (es) | 1999-09-10 | 2000-09-08 | Soluciones farmaceuticas de levosimendan. |
| AT00958562T ATE315937T1 (de) | 1999-09-10 | 2000-09-08 | Pharmazeutische lösung von levosimendan |
| PT00958562T PT1210085E (pt) | 1999-09-10 | 2000-09-08 | Solucoes farmaceuticas de levosimendano |
| PCT/FI2000/000761 WO2001019334A2 (en) | 1999-09-10 | 2000-09-08 | Pharmaceutical solutions of levosimendan |
| IL148379A IL148379A (en) | 1999-09-10 | 2002-02-26 | Pharmaceutical solutions of levosimendan |
| NO20021090A NO331989B1 (no) | 1999-09-10 | 2002-03-05 | Vandig intravenos infusjonsopplosning og intravenost infusjonskonsentrat omfattende levosimendan. |
| ZA200201828A ZA200201828B (en) | 1999-09-10 | 2002-03-05 | Pharmaceutical solutions of levosimendan. |
| IS6296A IS2244B (is) | 1999-09-10 | 2002-03-06 | Lyfjalausnir af levósímendani |
| BG106589A BG65827B1 (bg) | 1999-09-10 | 2002-04-05 | Фармацевтични разтвори от левосимендан |
| US10/703,565 US6943164B2 (en) | 1999-09-10 | 2003-11-10 | Pharmaceutical solutions of levosimendan |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI991925A FI109659B (fi) | 1999-09-10 | 1999-09-10 | Levosimendaanin farmaseuttisia liuoksia |
| FI991925 | 1999-09-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI19991925L FI19991925L (fi) | 2001-03-10 |
| FI109659B true FI109659B (fi) | 2002-09-30 |
Family
ID=8555263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI991925A FI109659B (fi) | 1999-09-10 | 1999-09-10 | Levosimendaanin farmaseuttisia liuoksia |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6730673B1 (cs) |
| EP (1) | EP1210085B1 (cs) |
| JP (1) | JP4708648B2 (cs) |
| KR (1) | KR100869752B1 (cs) |
| CN (1) | CN1203855C (cs) |
| AR (1) | AR025449A1 (cs) |
| AT (1) | ATE315937T1 (cs) |
| AU (1) | AU771027B2 (cs) |
| BG (1) | BG65827B1 (cs) |
| BR (1) | BRPI0013924B8 (cs) |
| CA (1) | CA2382013C (cs) |
| CO (1) | CO5180582A1 (cs) |
| CZ (1) | CZ303095B6 (cs) |
| DE (1) | DE60025627T2 (cs) |
| DK (1) | DK1210085T3 (cs) |
| EA (1) | EA005067B1 (cs) |
| EE (1) | EE05375B1 (cs) |
| ES (1) | ES2256034T3 (cs) |
| FI (1) | FI109659B (cs) |
| HK (1) | HK1049282B (cs) |
| HR (1) | HRP20020298B1 (cs) |
| HU (1) | HU228340B1 (cs) |
| IL (2) | IL148379A0 (cs) |
| IS (1) | IS2244B (cs) |
| ME (1) | ME00523B (cs) |
| MX (1) | MXPA02002423A (cs) |
| MY (1) | MY125984A (cs) |
| NO (1) | NO331989B1 (cs) |
| NZ (1) | NZ517605A (cs) |
| PL (1) | PL202356B1 (cs) |
| PT (1) | PT1210085E (cs) |
| RS (1) | RS50445B (cs) |
| SI (1) | SI1210085T1 (cs) |
| SK (1) | SK287154B6 (cs) |
| TR (1) | TR200200620T2 (cs) |
| TW (1) | TWI242434B (cs) |
| UA (1) | UA73954C2 (cs) |
| WO (1) | WO2001019334A2 (cs) |
| ZA (1) | ZA200201828B (cs) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
| FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
| CN100428937C (zh) * | 2003-10-30 | 2008-10-29 | 北京海合天科技开发有限公司 | 左西孟旦冷冻干燥组合物 |
| CN100367964C (zh) * | 2004-04-29 | 2008-02-13 | 王思清 | 左西孟旦-β环糊精包含物制剂 |
| JP2008530186A (ja) * | 2005-02-18 | 2008-08-07 | オリオン コーポレーション | 心不全治療法 |
| JP2010514778A (ja) * | 2006-12-28 | 2010-05-06 | オリオン コーポレーション | 非経口投与のためのレボシメンダン製剤 |
| US10046081B2 (en) | 2008-04-11 | 2018-08-14 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
| WO2012093404A2 (en) * | 2011-01-03 | 2012-07-12 | Gufic Biosciences Limited | Parenteral formulations of levosimendan |
| US20130096479A1 (en) * | 2011-10-18 | 2013-04-18 | St. Teresa Medical, Inc. | Method of forming hemostatic products |
| US9808529B2 (en) * | 2012-05-18 | 2017-11-07 | Luoda Pharma Pty Ltd | Liquid formulation |
| CN105106113B (zh) * | 2015-09-30 | 2019-07-26 | 济南康和医药科技有限公司 | 一种左西孟旦注射液及其制备方法 |
| PL3370693T3 (pl) * | 2015-11-06 | 2020-07-13 | Carinopharm Gmbh | Ulepszone preparaty lewosimendanu do podawania dożylnego w postaci roztworów do wlewów lub wstrzykiwań i koncentratu do wlewów |
| CA3004734A1 (en) | 2015-11-12 | 2017-06-18 | St. Teresa Medical, Inc. | A method of sealing a durotomy |
| CN108261398A (zh) * | 2016-12-30 | 2018-07-10 | 齐鲁制药有限公司 | 一种含有左西孟旦的供注射用药物制剂及其制备方法 |
| WO2019089717A1 (en) | 2017-11-02 | 2019-05-09 | St. Teresa Medical, Inc. | Fibrin sealant products |
| CN111474289A (zh) * | 2019-10-31 | 2020-07-31 | 武汉嘉诺康医药技术有限公司 | 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法 |
| CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
| CN111514147B (zh) * | 2020-05-12 | 2021-09-17 | 成都欣捷高新技术开发股份有限公司 | 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法 |
| US11760730B2 (en) | 2021-01-11 | 2023-09-19 | Navinta, Llc | Process for the preparation of high purity Levosimendan |
| WO2023027670A2 (en) * | 2021-08-23 | 2023-03-02 | Tum Ekip Ilac Anonim Sirketi | Lyophilized levosimendan compositions |
| CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英（江苏）药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
| CN116473930B (zh) * | 2023-05-17 | 2023-12-15 | 山东泰合医药科技有限公司 | 一种注射用左西孟旦及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| GB9606474D0 (en) | 1996-03-27 | 1996-06-05 | Orion Yhytmo Oy | Method for obtaining pure enantiomers of a pyridazinone derivative |
| GB9614098D0 (en) * | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
| FI980902A7 (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
| FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
-
1999
- 1999-09-10 FI FI991925A patent/FI109659B/fi active
-
2000
- 2000-08-09 UA UA2002042873A patent/UA73954C2/uk unknown
- 2000-08-11 MY MYPI20003682A patent/MY125984A/en unknown
- 2000-08-30 AR ARP000104525A patent/AR025449A1/es not_active Application Discontinuation
- 2000-08-30 TW TW089117581A patent/TWI242434B/zh not_active IP Right Cessation
- 2000-09-06 CO CO00067212A patent/CO5180582A1/es active IP Right Grant
- 2000-09-08 ES ES00958562T patent/ES2256034T3/es not_active Expired - Lifetime
- 2000-09-08 CN CNB008126453A patent/CN1203855C/zh not_active Expired - Lifetime
- 2000-09-08 KR KR20027002923A patent/KR100869752B1/ko not_active Expired - Lifetime
- 2000-09-08 WO PCT/FI2000/000761 patent/WO2001019334A2/en active Search and Examination
- 2000-09-08 DE DE60025627T patent/DE60025627T2/de not_active Expired - Lifetime
- 2000-09-08 SK SK327-2002A patent/SK287154B6/sk not_active IP Right Cessation
- 2000-09-08 EP EP00958562A patent/EP1210085B1/en not_active Expired - Lifetime
- 2000-09-08 NZ NZ517605A patent/NZ517605A/en not_active IP Right Cessation
- 2000-09-08 AT AT00958562T patent/ATE315937T1/de active
- 2000-09-08 RS YUP-169/02A patent/RS50445B/sr unknown
- 2000-09-08 HU HU0202749A patent/HU228340B1/hu unknown
- 2000-09-08 HK HK03101189.6A patent/HK1049282B/zh not_active IP Right Cessation
- 2000-09-08 SI SI200030801T patent/SI1210085T1/sl unknown
- 2000-09-08 DK DK00958562T patent/DK1210085T3/da active
- 2000-09-08 MX MXPA02002423A patent/MXPA02002423A/es active IP Right Grant
- 2000-09-08 IL IL14837900A patent/IL148379A0/xx active IP Right Grant
- 2000-09-08 ME MEP-2008-866A patent/ME00523B/me unknown
- 2000-09-08 HR HR20020298A patent/HRP20020298B1/xx not_active IP Right Cessation
- 2000-09-08 US US10/070,689 patent/US6730673B1/en not_active Expired - Lifetime
- 2000-09-08 TR TR2002/00620T patent/TR200200620T2/xx unknown
- 2000-09-08 JP JP2001522969A patent/JP4708648B2/ja not_active Expired - Lifetime
- 2000-09-08 PL PL354028A patent/PL202356B1/pl unknown
- 2000-09-08 PT PT00958562T patent/PT1210085E/pt unknown
- 2000-09-08 CZ CZ20020788A patent/CZ303095B6/cs not_active IP Right Cessation
- 2000-09-08 BR BRPI0013924A patent/BRPI0013924B8/pt not_active IP Right Cessation
- 2000-09-08 AU AU70044/00A patent/AU771027B2/en not_active Expired
- 2000-09-08 EA EA200200348A patent/EA005067B1/ru not_active IP Right Cessation
- 2000-09-08 EE EEP200200129A patent/EE05375B1/xx unknown
- 2000-09-08 CA CA002382013A patent/CA2382013C/en not_active Expired - Lifetime
-
2002
- 2002-02-26 IL IL148379A patent/IL148379A/en unknown
- 2002-03-05 NO NO20021090A patent/NO331989B1/no not_active IP Right Cessation
- 2002-03-05 ZA ZA200201828A patent/ZA200201828B/xx unknown
- 2002-03-06 IS IS6296A patent/IS2244B/is unknown
- 2002-04-05 BG BG106589A patent/BG65827B1/bg unknown
-
2003
- 2003-11-10 US US10/703,565 patent/US6943164B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI109659B (fi) | Levosimendaanin farmaseuttisia liuoksia | |
| FI84315C (fi) | Foerfarande foer framstaellning av en stabil, vattenhaltig, injekterbar piroxikamloesning. | |
| US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
| US20090221622A1 (en) | Topotecan ready to use solutions | |
| BG107748A (bg) | Фармацевтичен състав на дронедарон за парентерално приложение | |
| AU2004314154B2 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| CA2338324C (en) | Stabilized carvedilol injection solution | |
| PL202945B1 (pl) | Kompozycja farmaceutyczna zawierająca erytropoetynę, fiolka i sposób hamowania wzrostu drobnoustrojów w tej kompozycji | |
| US20090117205A1 (en) | Quinolone-containing medicinal composition | |
| MXPA03002770A (es) | Infusion de ciprofloxacina con un contenido de acido reducido y estable al almacenamiento. | |
| US20040019075A1 (en) | New formulation for the parenteral application of crobenetine | |
| US20110015221A1 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| HK1091146B (en) | New use, pharmaceutical preparations as well as a process for their production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: ORION CORPORATION Free format text: ORION CORPORATION |